Yauk Carole L, Aardema Marilyn J, Benthem Jan van, Bishop Jack B, Dearfield Kerry L, DeMarini David M, Dubrova Yuri E, Honma Masamitsu, Lupski James R, Marchetti Francesco, Meistrich Marvin L, Pacchierotti Francesca, Stewart Jane, Waters Michael D, Douglas George R
Environmental Health Science and Research Bureau, Health Canada, Ottawa, ON, Canada.
Marilyn Aardema Consulting, Fairfield OH, USA; Bioreliance, MD, USA.
Mutat Res Genet Toxicol Environ Mutagen. 2015 May 1;783:36-54. doi: 10.1016/j.mrgentox.2015.01.008. Epub 2015 Jan 24.
This workshop reviewed the current science to inform and recommend the best evidence-based approaches on the use of germ cell genotoxicity tests. The workshop questions and key outcomes were as follows. (1) Do genotoxicity and mutagenicity assays in somatic cells predict germ cell effects? Limited data suggest that somatic cell tests detect most germ cell mutagens, but there are strong concerns that dictate caution in drawing conclusions. (2) Should germ cell tests be done, and when? If there is evidence that a chemical or its metabolite(s) will not reach target germ cells or gonadal tissue, it is not necessary to conduct germ cell tests, notwithstanding somatic outcomes. However, it was recommended that negative somatic cell mutagens with clear evidence for gonadal exposure and evidence of toxicity in germ cells could be considered for germ cell mutagenicity testing. For somatic mutagens that are known to reach the gonadal compartments and expose germ cells, the chemical could be assumed to be a germ cell mutagen without further testing. Nevertheless, germ cell mutagenicity testing would be needed for quantitative risk assessment. (3) What new assays should be implemented and how? There is an immediate need for research on the application of whole genome sequencing in heritable mutation analysis in humans and animals, and integration of germ cell assays with somatic cell genotoxicity tests. Focus should be on environmental exposures that can cause de novo mutations, particularly newly recognized types of genomic changes. Mutational events, which may occur by exposure of germ cells during embryonic development, should also be investigated. Finally, where there are indications of germ cell toxicity in repeat dose or reproductive toxicology tests, consideration should be given to leveraging those studies to inform of possible germ cell genotoxicity.
本次研讨会回顾了当前的科学研究,以提供信息并推荐关于生殖细胞遗传毒性测试使用的最佳循证方法。研讨会的问题及主要成果如下:(1)体细胞中的遗传毒性和致突变性检测能否预测生殖细胞效应?有限的数据表明,体细胞检测能检测出大多数生殖细胞诱变剂,但存在诸多重大疑虑,这使得在得出结论时需谨慎。(2)是否应进行生殖细胞检测,何时进行?如果有证据表明一种化学物质或其代谢产物不会到达目标生殖细胞或性腺组织,那么尽管体细胞检测有结果,也无需进行生殖细胞检测。然而,对于有明确性腺暴露证据且在生殖细胞中有毒性证据的阴性体细胞诱变剂,可考虑进行生殖细胞致突变性检测。对于已知会到达性腺区室并暴露生殖细胞的体细胞诱变剂,可假定该化学物质为生殖细胞诱变剂,无需进一步检测。不过,为了进行定量风险评估,仍需要进行生殖细胞致突变性检测。(3)应实施哪些新检测方法以及如何实施?迫切需要开展关于全基因组测序在人类和动物可遗传突变分析中的应用研究,以及将生殖细胞检测与体细胞遗传毒性检测相结合的研究。重点应放在可能导致新发突变的环境暴露上,特别是新认识到的基因组变化类型。还应研究在胚胎发育过程中生殖细胞暴露可能发生的突变事件。最后,在重复剂量或生殖毒理学测试中有生殖细胞毒性迹象时,应考虑利用这些研究来了解可能的生殖细胞遗传毒性。